Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 4 Interventional

Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

ClinicalTrials.gov ID: NCT07624526

Public ClinicalTrials.gov record NCT07624526. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.

Study identification

NCT ID
NCT07624526
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 4
Lead sponsor
Emory University
Other
Enrollment
75 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 95 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2026
Primary completion
Jul 31, 2028
Completion
Jul 31, 2028
Last update posted
Jun 2, 2026

2026 – 2028

United States locations

U.S. sites
3
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Emory Clinic Atlanta Georgia 30322
Emory Clinic at Executive Park Atlanta Georgia 30329
Emory Orthopaedics and Spine Center Atlanta Georgia 30329

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07624526, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 2, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07624526 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →